Daiichi Pharmaceutical Co., Ltd. (President: Kiyoshi Morita; Head Office: Tokyo) and Suntory Limited (President: Nobutada Saji; Head Office: Osaka) are pleased to announce that the jointly-owned new pharmaceutical company Daiichi Suntory Pharma Co., Ltd. (President: George Nakayama; Head Office: Tokyo) was established on December 27, 2002.
The new company, 66% owned by Daiichi and 34% held by Suntory, was created by transferring all the business of Suntory's Pharmaceutical Division and has started operations from January this year.
Corporate Profile:
Daiichi Suntory Pharma Co., Ltd.
| Head Office: |
5-7-2, Kojimachi, Chiyoda-ku, Tokyo |
| President: |
George Nakayama |
| Date of Establishment: |
December 27, 2002 |
| Capital: |
¥1 billion |
| Ownership: |
66% by Daiichi Pharmaceutical Co., Ltd.
34% by Suntory Limited |
| Employees: |
340 |
| Sales Estimates: |
¥2.5 billion (January-March 2003)
¥10.0 billion (Daiichi's full fiscal year ending March 2004)
|
| Primary Business: |
Research, development, manufacture and sale of pharmaceuticals
|
| Subsidiaries: |
Daiichi Suntory Biomedical Research Co., Ltd. |
| |
(1-1-1 Wakayamadai, Shimamoto-cho, Mishima-gun, Osaka) |
| |
Suntory Pharmaceutical, Inc. |
| |
(Fort Lee Executive Park, 2 Executive Drive, Fort Lee, NJ 07024, USA) |
| |
Suntory Pharmaceutical Research Laboratories, LLC. |
| |
(One Kendall Square, Building 1400, Cambridge, MA 02139, USA) |
Products in the Market:
Products in the Pipeline:
|
